|  |
| --- |
| **Advanced Therapies Gene Modification Safety Committee****Approved Clinical Risk Assessment Report** |

|  |
| --- |
| **ATMP Details** |
| Type of ATMP |  | Clinical Trial or Medicine? |  |
| ATMP title |  |
| Lead Clinician or PI: |  |
| Planned start date at site: |  | Planned end date at site: |  |
| NHS Lothian Location(s): |  |
| **Approvals in Place:** |  |  |  |

|  |
| --- |
| **ATGMSC Review Details** |
| **RA Report** **Version and Date** |  |
| **Lead Reviewer** |  |
| **Contributing Committee Members** |  |
| **Date of Committee review** |  |
| **Regulatory Approvals (Clinical trials)** | **Are there conditions to approval? MHRA**: Yes/No **REC:** Yes/No**Do these conditions impact on risk and safety in relation to the ATMP?**  |
| **Documents reviewed by ATGMSC** | **Initial Review (pre ATGMSC approval)** | **Amendments** |
| **Comments** |  |
| **ATGMSC Decision** |  | **Date** |  |

|  |
| --- |
| **Risk Assessment Report of ATMP to be used in NHS Lothian Clinical Areas** |
|  | **Committee Comments** |
| **Advanced Therapy Medicinal Product Details** |  |
| Type of ATMPClinical Trial or Medicine? |  |
| **Section 1: Application Details**  |  |
| **1.1a Study Details (Clinical Trials)** |  |
| **1.1b (ATMP details) – licensed or unlicensed medicines** |  |
| 1.2 Principal Investigator1.3 Role of PI1.4 PI Mentor1.5 Main Study Contact1.6 Pharmacy Contact |  |
| **Section 2: Approvals, Consents, Notifications and Licences** |  |
| **Section 3: Lay Summary of Research** |  |
| **Section 4: Scientific Detail of the Research** |  |
| **Section 5: Details of the GM(O) Products** |  |
| 5.1 – Full Description of the Host Microorganisms5.2 – Full Description of the Vector(s)5.3 – Full List and Description of the Inserts(s)5.4 – In vitro use of the GMO5.5 – In vivo use of the GMO |  |
|  |
|  |
|  |
|  |
| **Section 6: Risks to Human Health** |  |
| 6.1 – Unaltered Host Organisms/Vectors6.2 – Inserts6.3 – Modified Host Organisms/Vectors6.4 – Recombination6.5 – Hazards to Human Health6.6 – Assessment of Risk6.7 – Interim Assignment of GM Class (Human Health) |  |
|  |
|  |
|  |
|  |
|  |
|  |

|  |  |
| --- | --- |
| **Section 7: Risk to the Environment** |  |
| 7.1 – Unaltered Host Organisms/Vectors7.2 – Inserts7.3 – Modified Host Organisms/Vectors7.4 – Recombination7.5 – Environmental Hazards7.6 – Likelihood of Release7.7 – Contained Use or Deliberate Release7.8 – Assessment of Risk7.9 – Interim Assignment of GM Class (Environmental Risk) |  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
| **Section 8: Final Assignment of GM Class and Containment Level** |  |
| **Section 9: Occupational Health** |  |
| 9.1 – Health Effects9.2 – Medical Risk Assessment9.3 – Pre-Exposure Arrangements9.4 – Post-Exposure Action9.5 – Antibiotic Treatment or Chemoprophylaxis9.6 – Health Surveillance Required9.7 – Additional Notes & Comments |  |
| **Arrangements to Control Risk** |  |
| **Section 10: Patient Considerations** |  |
| 10.1 - Administration to Patient |  |
| 10.2 - Patient Care |  |
| 10.3 - Patient Follow up |  |
| **Section 11: Staff Considerations** |  |
| 11.1 Staff Safety and Surveillance |  |
| **Section 12: Waste Management Considerations** |  |
| 12.1 – Waste Management |  |

|  |  |
| --- | --- |
| **Section 13: Pharmacy and Product Preparation/Storage and Transport** |  |
| 13.1 – Manufacture  |  |
| 13.2 – Shipment/GMP receipt |  |
| 13.3 – Storage |  |
| 13.4 – Preparation / Manipulation |  |
| 13.5 – Transfer to Administration Area |  |
| 13.6 – Chain of custody |  |
| 13.7 – Prescription |  |
| 13.8 - Disposal |  |
| **Section 14: Information, Instruction, Supervision and Training** |  |
| 14.1 – Relevant SOPs14.2 - Training |  |
| **Section 15: Accommodation** |  |
| **Section 16: Personnel at risk** |  |
| **Section 17: Declarations and Approvals** |  |
| **Additional Committee Comments** |  |
|  |  |

|  |
| --- |
| **Summary of Changes from Version X to Version Y of Risk Assessment Report** |
| Section | Summary of Change | Reason for Change |
|  |  |  |

|  |
| --- |
| **Approvals and Signatures** |
| **This study has been risk assessed by the ATGM Safety Committee and approved to proceed within NHS Lothian Clinical Areas mentioned.****The Risk Assessment Report is approved by the signatories below following ATGMSC review of the Risk Assessment and accompanying documents. Subsequent amendments to these documents, or any other changes that may affect this risk assessment, must be submitted to the ATGMSC for review and approval.****Any amendments that affect the information in this report will result in the issue of a new version. Any other amendments may require a letter of approval from the ATGMSC but no update to this report.****Signature of PI/Clinician: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** **Date:** **Signature of Chair: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date:****Signature of BSO: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date:**  |